MiNA Therapeutics
Troels joined MiNA in 2021 and leads chemistry research and strategy. Troels brings over 20 years of leadership in RNA therapeutics research, drug discovery and company building. He previously led RNA therapeutics research at Roche as Chief Technology Officer and VP Research, Roche Innovation Centre Copenhagen. Prior to its acquisition by Roche, Troels held the same role at Santaris where he worked for 11 years and founded its predecessor companies Cureon and Exiqon. Troels has a PhD in Bioorganic Chemistry from the University of Copenhagen.
This person is not in any offices
MiNA Therapeutics
Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.